Have a documented diagnosis of Graves' Disease confirmed by the presence of thyroid-stimulating hormone receptor antibodies (TRAbs) by medical history or screening laboratory assessment
Have a pre-existing diagnosis of TED or, conversely, no evidence of TED at the ophthalmological examination performed during screening
You may not be if
Previously treated with radioactive iodine (RAI) therapy or underwent total thyroidectomy
Received any dose of levothyroxine, desiccated thyroid extract, or T3 within 6 weeks before screening
Current treatment with teprotumumab or exposure to teprotumumab within 15 weeks prior to screening
History of hyperthyroidism not caused by Graves' disease (eg. toxic adenoma, or toxic multinodular goiter) within 6 months before the screening visit
Pregnant or lactating women
Clareo Health | Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
